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Abstract: 
Introduction: Radiation n1ucositis is a very common acute morbidity su fered by almost 
all patients undergoing radiotherapy to the head and neck region. Mater als and Methods: 
This is a prospective double blind randomized control trial comparing t pical application 
of natural honey in mucositis induced by che1no-radiotherapy in nasopl aryngeal cancer. 
One hundred twenty patients were treated with chemo-radiotherapy usi g cisplatinun1. 
Radioth~:rapy consists of 70Gy in 35 fractions over 7 weeks period alo g with 30mg 
parenteral \Veekly cisplatinum was administered. Sixty (60) patients we ·e subjected to 
j 
topical application of honey before and after each fractions of radiother~py. The 
n1ucositis, dysphagia and dry mouth were assessed using RTOG gradink systetn. Weekly 
body weight n1onitoring, the EORTC QLQ-H&N35 and general EORTb QLQ-C30 
questionnaire were recorded before and after radiotherapy. Results: ThJre were 82 1nales 
and 38 f<~male with a median age of 48 years (I O-S I years) in this studyj The compliance 
I 
to honey and placebo application was poor in our patient population with only 49-patients 
l 
(40.8°/o) accepted con1plete course; 21 (17.5o/o)-incon1plete and remainir1g refused 
application including 6-patients developed adverse effects in the fonn ~f bun1ing mucosal 
pain. The concurrent chemotherapy was accepted in 51 ( 42.5%) patient~, incomplete in 
6 7 (55. 8%) patients and not received in 2 ( 1.6%) patients. The quality of life in Head & 
Neck specific scale changed fron1 42 to 54 points in study arm and 43 tp 54 points in 
control arn1. The grade4 n1ucositis appeared to be less in honey treated larm co1npared to 
controls \Vhoever other grades of mucositis or weight changes was equt'vocal in both anns 
Conclusions: Due to non-co1npliance of topical application of study ag nts, there was no 
significant difference in mucositis, body weight, dysphagia grade or drt mouth in study 
and control group of patients. Proper selection of honey, method of ap lication of honey 
with mucosal adhesion properties might reveal i1nprovement of n1ucos tis in future 
l 
! 
research : 
Key words: Radiation 1nucositis, chetnotherapy, honey, treatment, res*onse, body weight 
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Introduetion 
Radiation induced n1ucositis is a well known accompaniment of radiati n treatn1ent to the 
head and neck area. Mucositis leads to oral ulceration causing pain and ysphagia to 
discontinuation of treatment or gap during radiotherapy. A gap during t e course of 
radiotherapy leads to loss of local control in many cancers including he d and neck 
cancers 1 • The incidence of radiation mucositis varies due to field size, c -morbid mucosal 
condition and systen1ic disease, orodental infection. Modern radiothera y teclmiques like 
hyperfra·~tionation, accelerated fractionation, CHART has increased th rate of 
mucositis2-3. Currently administration of chemotherapy as radiosensitiz r (concurrent 
che1notherapy) has shown to improve survival in head and neck cancer ompared to 
conventional fractionated radiotherapy4-5. The occurrence of 1nucositis s a dose limiting 
toxicity in the n1anagement of head and neck cancers undergoing radiot1erapy. Systemic 
disease like diabetes 111ellitus and connective tissue diseases and re-irra iation can also 
increase::; the rate of mucositis. The severe fonn of mucositis (NCI CT grade3 & 4) are 
I 
i 
sytnpton1atic and affect the health and outcome of cancer in the above ~egion. 
Currently the pathophysiology of induction of radiation 1nucositis is ch~nging. The 
current research has identified multi-step process for radiation mucositi~. The process of 
radiation n1ucositis goes through 4-defined steps6. Therefore no single ~reatlnent is 
I 
effective in radiation n1ucositis as they do not address all aspects of mupositis. Currently 
there is no standard of care for the treatment of radiation mucositis7. Fr
1 
quent salt soda 
solution oral rinse is the most common 1nanagement of mucositis in m ny radiotherapy 
centers. Fron1 the plethora of agents being tried in radiation 1nucositis; tnifostine, hun1an 
placental extract etc has shown some response fro1n the outcome of tne a-analysis. 
Radiotherapy techniques such as oral shielding and IMRT are used to r~duce the intensity 
of tnucositis. Honey is a mixture of nectar, aerodigestive tract of the horey bee and part 
of the honey coin b. It has tissue repairing, epithelization, caloric prop ties. It too 
reduces intlan1n1ation and clear oral pathogens, an earlier study on the ole of honey in 
the n1anage1nent of radiation tnucositis has shown to reduce severe n1u ositis and 
111ucosal pain8-9. Fron1 the earlier experience on the use of honey in rad ation n1ucositis 
we proposed a n1ulticenter randomized trial in the manage1nent of radia ion mucositis 
induced by concurrent chemoradiotherapy in the management ofnasop aryngeal cancer. 
l\1aterials and Method 
This is a prospective multi-center double blind randomized trial compa ing the difference 
of radiation 1nucositis between honey and placebo group of patients wit nasopharyngeal 
cancers on concurrent chemoirradiation. The patients were recruited fr Hspital 
Universiti Sains Malaysia, Hospital Kuala Lumpur, and Sarawak Gene 1 Hospital. The 
case selection includes locally advanced nasopharyngeal cancer patient with histological 
proof of cancer, good performance status age between 15-85 years. Patents with 
unlocalized tu1n0L patients suffering from connective vascular disease ere excluded 
fi:01n the study. 
I 
Randomization I 
The randomization was controlled centrally at USM. The doctors, reseJrchers and patient 
I 
did not kno\v the study agent. The research assistant recruits patients. 1)he patients were 
evaluated using nasoendoscopy, contrast enhanced CT scan of the hea~ and neck, full 
blood count, liver and kidney chen1istry vvere performed prior to recruitment of patients. 
I 
I 
I 
I 
! 
Treatment with research agents 
I 
I 
1 
The patients belong to study arm were treated with concurrent chemo-1adiotherapy and 
honey treatn1ent. About 20 ml of the research 1naterial was allowed toieep inside mouth 
and to s·wish and swallow the whole content 15 minutes before, 15 mi utes after and 6 
hours after radiotherapy. The treatn1ent continued throughout the cour e of radiotherapy. 
The control groups of patients were given along-with sim~la~ concurrett chemo-
radiotherapy and dose schedule throughout the course ofrad1otherapy. 1 
I 
l 
I 
I 
! 
Rwliul herapy 
The aclmi ni stration of rae! iotherapy consists of three phases. The phase- consists of the 
whole pnmary tumor extent plus safe margin and draining lymphatic re · ions. The typical 
ticld extc·ncls from base of the skull until clavicular area that includes th whole extends 
of mucosa. Usuall y a 6 MV x-ray was used from a linear accelerator. T e sp ine was 
e'\cluded from the beam after 44Gy and the final boost was de livered to, the primary 
tu mor plus 2 centimeters of safe margin (Fig- 1-a-d) . The bulky nodal 
up to 70Gy. Care was taken to reduce gap during radiotherapy. 
Phase-:: Phase-II Phase-III 
Fig- ! a-d . Serial simulator films of phase-I, phase-II, phase III 
lower neck field was used in phase-! & II only. Please note 5HVL 1 
brain. brain stem, orbit, spinal cord and lungs. 
( 'hemotherapy 
were boosted 
shields to protect 
C isplatinum single agent chemotherapy d was administered through in ravenous route 
concurmntly to a dose of 30 mg in 1 hour infusion once weekly for up !o 7 weeks. 
Parenteral hydration, granisetron and dexamethasone were used for pr1vention of nausea 
and vomiting. T he chemotherapy was administered on the I st working · ay of the week 
before radiotherapy. 
Enduatiun of mucositis and body "'eight 
The mucositis was graded using RTOG grading system. The evaluation J as done every 
week and recorded. The dysphagia and skin reaction too was graded as r r the RTOG 
grading system (Fig- 2a-c). The lean body weight was also recorded ev ·y week using 
same wei.ghing machine . 
I 
------··---.-) 
Fig-2a. Schematic diagram 
cavity showing 9-sites of the ral cavity 
required to be evaluated durinr: mucositis 
assessment. 
Fig-2b. A case of severJ (RTOG 
grade-III) cancer treatmen,~ related 
mucositis. Please note the !confluent 
mucositi s all over the dt·sum of 
tongue. The patient also suffered 
from severe dysphagia. 
Fig-2c. Close-up picture ff the oral 
mucosa area on the bucc~ aspect of 
cheek showing breach in the continuity 
of the mucosa. Note e ythema in 
addition to ulceration. 
Evaluation of quality of life 
The quality of life was recorded before and after radiotherapy using EO TC C-30. and 
Head & Neck C35 questionnaire in Bahasa Malaysia language. 
Statistical Analysis 
The patim1t's data were analyzed using SPSS-11 software and multivarJ te analysis. The 
results were compared using chi-square test. r 
Results 
I 
One hundred twenty nasopharyngeal cancer patients were recruited fro~ three centers 
fron1 Malaysia. The median age of the study and control arm of patient~ was 47 and 50 
years in controls and study groups of patients that range from 10-81 yets. The race 
distribution was as follows Malays (30%), Chinese24o/o, Ibans (23o/o) aid other races in 
7.5o/o of population. There were 40 and 42 males and 20 and 18 female in the control 
and study groups of patients (Table-1 ). Study was conducted between J~nuary 2005 to 
July 2007 at Hospital Universiti Sains Malaysia, Hospital Kuala LumpJr, and General 
Hospital Sarawak at a ratio of 24:16:80 patients. The stage distributio1~ and racial 
! 
distribution of patients were similar in both groups (Table 1 ). 
, . 
Table- I. Patients demography and disease profile 
Control Group Study Grm p 
Nun1ber 60 60 
Gender (l\1ale) 40 (33%) 42 (36%) 
Gender (F etnale) 20 (16.5%) 18 (15o/o) 
Age 47(19-71) 50(10-81) 
Stage(T 1-4) 19/18114/9 15/16/17/12 
HPE type# 4(3%)/23 (19%)/32 (26%) 4(3%)/27( 22o/o)/27(22%) 
, Race* 18116/15111 18113113/ 6 
! 
I Tl 15 19 
I T? I - 16 18 ! 
T3 17 14 
T4 12 9 
No 15 12 
; Nl 
i 18 8 I 
! N? 19 25 
IN: I ~ 8 15 
i 
I Gl 4 4 I 
I o2 23 27 
I 
I 
! 03 32 27 
I 
! Poor ODH 10 
! 
12 i 
I Good ODH 47 42 
Died 1 4 
Tumor close 70Gy 70Gy I 
I Fieldsize 
! 
205.5cm2 210.4cm.t 
*Malay (30o/o)/Chinese(24.2%)/lban (23.3o/o)/Bidayuh 7.5%,0thers (1~o/o); 
# HPE G 1 6o/o, 02 42o/o, 03 49% I 
I 
I 
I 
Concurrent chemoradiotherapy. 
Our patients \Vere offered 30 tng of cisplatinum parenterally on the 1st 
radiotherapy. Out of 120 patients 51 ( 42o/o) received co1nplete course of ingle agent 
cisplatim.un che1notherapy whereas inco1nplete cycles was delivered to 7 patients (57°/o) 
where the reason of discontinuation was incomplete. (Table-2) 
Compliance of honey treatment: Out of total 120 patients 49 patients ac ually received 
cotnplete course of honey/placebo agents. 44 (36%) refused research a ent treatn1ent due 
to poor taste of the research n1aterial. Incomplete treatment was offered to 21 (17%>) 
patients and adverse effect was seen among 6-patients mainly due to serere burning 
sensation in oral1nucosa. (Table-2) ! 
I 
I Table-2. Con1pliance to treatlnent 
Control Honey I 
i Nmnber recruited 120(100%) 120 I 
Cotnpletely received 51(42.5%) 49 (40.8° vo) 
Inc01nplete cycles* /treatment 67(55.8o/o) 21 (17.5~ 10) 
Insufficient reason 02(01.6%) i 
i 
I Refused treatn1ent mid-RT 44 (36.7f!o) 
l Adverse effect (burning pain) 
I 
06 (So/o)j 
' 
I 
* Incon1p lete chetnotherapy :2-weeks- 9, 3 -weeks-11, 4 weeks-8, /s weeks-13, and 6 
k .... .., . \vee s _, _, patients I 
I 
I 
J\1/ucositis prevalence 
Mucositi~; vvas evaluated routinely every week. The grade 1-4 mucositis wer e similar in 
control and study arm of patients. The grade 3/4 mucositis was marginal 11Y lo 
treatn1ent con1pared to placebo group of patients (Table 3 ). Similarly gn de 3 
was also lovver an1ong honey treated group of patients (Table 4). Thera e of 
was ahnost sin1ilar (Table-S). 
Table-3. Mucositis Pattern 
l Honey Treated Arm Control Arm 
Weeks 0 1 2 .., 4 0 I 2 3 ~ .) 
: 
1 83.2 16.9 86.7 13.3 I I 
12 39 54.2 6.8 53.4 41.4 5.2 ! 
i i 
!3 22.6 52.8 20.8 3.8 26 60 14 
i i 
4 16.3 51 24.5 8.2 14 60.5 25.6 j 
l 
5 13.6 50 27.3 9.11 7.7 51.3 30.8 10.3 ! l 
6 11.4 42.9 31.4 11.4 2.9 8.1 48.6 29.7 8.1 M 
I I 
17 6.9 44.8 24.1 17.2 6.9 9.1 45.5 21.2 18.2 ~ h- : 7.7 46.2 30.8 15.4 12.5 31.3 43.8 12.5 I i 
I 
I 
I 
I 
I 
wer in honey 
/4 dysphagia 
xerosto1nia 
Table-4. Pattern of Dysphagia 
Honey Treated Arm Control Arm 
Weeks 0 1 2 3 4 0 1 2 3 ~ 
1 83.1 18.6 90 13.3 
I 
2 39 44.1 6.8 53.4 41.1 5.2 l 
... 22.6 66 9.4 3.8 26 60 14 .) 
4 16.3 63.3 18.4 6.1 14 60.5 25.6 
15 13.6 59.1 20.5 13.6 7.7 51.3 30.8 10.3 
6 11.4 27 16.2 8.1 48.6 29.7 8.1 5.5 
17 6.9 20 26.7 3.3 9.1 45.5 21.2 18.2 6.1 
8 7.7 30.8 38.5 23.1 12.5 31.3 43.8 12.5 
Table-5. Pattern of Xerostemia 
I 
r Honey Treated Ann Control Arm ' 
i 
: 
I 
i i Weeks 0 1 2 3 4 0 1 2 3 4 
! 
f 1 88.1 11.9 88.3 11.7 
i 
I 
2 52.5 44.1 3.4 53.4 46.6 
3 37.7 54.7 5.7 1.9 28 66 6 
4 20.8 64.4 12.5 2.1 20.9 60.5 18.6 
~ 19 54 23.8 2.4 7.7 53.8 33.3 5.1 8.6 62.9 22.9 5.7 8.1 48.6 35.1 8.1 
I 
17 7.1 53.6 21.4 14.3 3.6 12.5 40.6 28.1 18.8 
I 
!8 7.1 57.1 14.3 21.4 6.3 37.5 43.8 12.5 
L 
( 'hange oh body weight 
The regular body weight measurement revealed a gradual reduction in t ;te body weight 
(median 5 kg) Table-6. 
Table-6. Change of body weight during radiotherapy 
Honey Placebo 
Mean in Kg Median in Kg Mean in Kg Median in Kg 
Week. I 60.16 61.4 59.41 60.4 
Week.2 58.94 59 58.28 59 
\Veek.3 57.82 58.75 57.26 57.55 
'J\1eek.4 54.98 57 55.97 57.2 
I 'A1eek.5 54.34 54.25 54.48 55.4 
I \Veek.6 52.82 52.5 52.99 52.15 
Week.7 51.4 51 49.47 49 
\Veek.8 53.8 55 54.93 54.4 
Change in the quality of l~fe 
The general quality of life was evaluated using EORTC general quality! of life 
I 
questionnaire. There was about lOo/o difference in the quality of life be~ore and after 
treatn1ent in both placebo and honey treated group of patients (Fig-3 ). the deterioration 
of EORTC C30 QlQ was less marked in honey treated arm than contra s. 
Figure-3.COinparative QoL graph show slope ofEORTC H&N and gen ral QoL 
60 
50 
40 
30 
20 
10 Xo36 8.07 
7093 
-Honey 
QoL C30 Honey 
=-=» QoL 29-30 Honey 
0 
0
, ° Control 
- QoL C30 Control 
......,........ QoL 29-30 Control 
{) +---------~----------~--------~--------~ 
!~efore After 
Discussi,on 
Oral mucositis is an acute effect of the radiation exposure to the oral m~cosa that exceed 
tissue tolerance. The above exposure leads to a battery of pathophysiol~gical and 
in1n1unological consequences that ultin1ately leads to inflatnmation, vas~ularity, and 
I 
cellular loss, release of cytokine, ulceration, infection and healing, The rim ofthe 
radiation mucositis n1anagen1ent should be multi-targeted that could pr vent various steps 
of pathogenesis natnely initiation, primary datnage response, signal an1 lification, 
ulceration and healing6. In this study we utilized pure natural honey in t 1e prophylactic 
111anagernent of chen1oirradiation-induced 1nucositis amongst nasophar ngeal cancer 
patients. There \Vas non-cotnpliance to honey and placebo treatn1ent du to non-
palatability and con1pliance to honey and placebo agents leading- to inc ased dropout of 
patients in the evaluation. There was no significant improvement in the tnucositis 
an1ongst honey treated group of patients. However there vvas a trend tow ds reduction 
incidence ofRTOG grade-3-4 mucositis among honey treated group ofp tients compared 
to controls. These findings could be less number of patients compliant to honey and 
placebo treatn1ent. The evaluation of body weight too showed equivocal eading in honey 
and control group of patients. 
tvlanagem.ent of oral n1ucositis is changing. A huge nun1ber of agents an tnethods have 
been practiced in clinical trials, however, none of the agents or methods ave shown 
significact benefit to reduce radiation induced n1ucositis. In one of the eta-analysis by 
\J\1 othington et al 5-agents has been indicated to have so1ne benefit in or 1 mucositis such 
as placental extract, benzydatmine, antibiotic lozenges, glutamine and o al cooling agents 
those warrant fut1her clinical trial 10• The difficulties in the understandin of the results of 
such trials have been fu11her complicated due to the adoption of differet types of 
tnucositis grading system used by individual investigators. The WHO, TOG, NCI-CTC 
grading systen1s are tnost often used in the past, however they are notre reducible and 
inter-obs·erver variation of reporting might be great. Most of the trials d not include 
dental or oral surgeons in their trials. Very recently oral mucositis asses ment score 
( OiVlAS) have been devised to report mucositis objectively. The oral cality is divided in 
to 9 sub-sites natnely l.upper labial mucosa, 2.lower labial n1ucosa, 3-4 right and left 
buccal n:.ucosa, 5.right and 6.left lateral and undersurface of the tongue,
1
7.fl.oor of the 
mouth, 8.hard-palate and 9.soft-palate. The radiation mucositis are gradfd as redness or 
ulceration in each site. The combination of erythema and ulceration are 'considered as 
Otv1AS ~.core. It need training and education among participating invest gators to repo11 
accurately. A study conducted amongst 65 investigators showed consis ent reporting' 1. 
Honey is known to be antibacterial due to release of H202 at the tissue site, reduce 
inf1an1mation, protnote tissue repair, add nutrition and inhibit tnany co plitnentary 
cascade pathways oftnucositis pathogenesis 12. Honey act in tnucositis n multiple steps 
of tnucositis thus help alleviation of disco1nfort on various steps of n1u ositis. 
In a recent randomized study by Rashad et al 13 from Saudi Arabia studie the role of 
topical honey on the prophylaxis against chemoradiotherapy-induced tnu ositis. They 
studied the alteration of mucositis pattern among 20-oropharyngeal cane rs on 
chen1oradiotherapy treatment compared to controls receiving similar rad' therapy 
protocols. The patterns of oral pathogens were also reviewed. In their st y they noticed 
significant reduction of severe mucositis (p<O.OOS). Candida colonizatio and aerobic 
pathogen bacterial culture was reduced significantly in honey treated an compared to 
n1atched eontrols. 
Another study fron1 Iran by Motallebnejad and colleagues 14 studied the evelopment of 
oraltnucositis an1ong head and neck cancer patients on radiotherapy usi 
OMAS index . In their study arm, patients received 20 ml of natural ho y IS minutes 
before radiotherapy, 15 tninutes after radiotherapy and 6 hours after rad otherapy. The 
age n1atched control patients were treated with saline oral rinse. The m ositis score on 
OTvlAS s~ale \vas significantly reduced among honey treated patients 2 vs 8 at the end of 
6111 \Veek of radiotherapy. The 1nean weight loss in both groups was ana zed using the 
independent satnple t-test which was significantly high amongst controlb group of 
patients (p 0.0000). I 
i 
ln our earlier study on the role of topical honey in radiation mucositis ongst 40 head 
and neck cancer patients. We showed significant reduction in R TOG g 
nntcositts con1pared to controls. Instead of loosing weight, static or pos tive weight gain 
\\'aS obs·erved in the study arm8. Similar study in Japan revealed benefi s of pure natural 
honey in the painful stomatitis caused by radiation mucotitis9. Smirno et al from Russia 
studied to role of dagree "honey laminolact"to reduce post radiotherap intestinal 
con1plication an1ong pelvic tun1ors undergoing radiotherapy15 . 
The use of honey in cancer is widespread. In a pilot study, honey dress in was superior to 
c01npared paraffin dressing in terms of tame taken to healing. The author suggested 
n1ore recruitn1ent of patients to get better statistical difference. The study was 
pren1aturely closed due to less recruitment of cases, more follow up time required to 
evaluate r•esponse to intervention 16• 
Quality of life was evaluated using standard EORTC general and head a d neck specific 
quality of life. There was similar deterioration in the quality of life in bo h honey and 
placebo group of patients. 
Radiation tnucositis is kno,vn to cause oropharyngeal pain leading to dy phagia and 
decreased intake. The nutrition is further complicated by the loss of tast and feeling of 
nausea and votuiting and cancer induced anorexia. The resultant malnutt ition leading to 
\:veight loss (cachexia) and non-compliance to radiotherapy or chen1othe ·apy . In our 
study we observed n1edian weight reduction of -1 OI(g over the period o: irradiation. In a 
con1parative study suing honey and no treatinent the mean weight loss ~as 1 0.35 (0-
7I<g)~ whereas in the control group the mean weight loss was 6.3 0.53 cd-11 Kg). The 
above difference was statistically significant14 . In various studies in con,urrent chemo-
radiotherapy in head and neck cancers investigators advise total parente al nutrition to 
con1bat \Veight loss 17, ho\vever \Ve did not used any parenteral or entera~ feeding. 
I 
In conclusion, the current study did not showed significant mucositis cl+nges perhaps 
because of incomplete data from participating centers due to discontinutnce of honey 
treatment in the 111iddle of radiotherapy. The n1ain complaint was nauset and von1iting 
and son1e patients cotnplained of burning sensation on mucosa. The ab1ve effects might 
be due to poor quality of honey or peculiar response of concurrent che oradiotherapy-
induced n1ucositis. Further studies are needed with established mucosif s scale to observe 
any significant benefit in tnucositis. 
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R.atldomizati.op. No: 
IAEA Research Project: Phase-lli Randomized trial comparing.t· pical application 
of natural honey in the management of radiation mucositis among pati lnts undergoing 
radical radiotherapy for nasopharin:geal cancer. 
Name of the patient: 
Identity Card Number/Passport Nwnber: 
Hospital Number: 1 I·· J -b .. -.f ....... J . .f· . 1 j J· f f 
Age (in years): ITJ 
Sex: lv.l/ F 
Race: 
! . 
I 
I· 
! Any o1het non .. concerous medical problem: --------t-----
Perevious anticm1:cer treatment history 
Diagnosis: Nasophacyn.geal Cancer. 
Stage ~ .. AJcc system) 
Histology (Tissue· diagt}osis ) with reference number I 
r 
.--------oro-d.ental hygiene: loose teetbt-gingtvitist-cariesf·edentulousl Use o~ denture during 
(~. treatn1ent. . . · . . l 
l 
! 
I Chet~klist 
i 
;,. 
., 
I 
.. i 
I 
Radiotberapy Detalls 
Fields and field sizes 
Parallel <)ppased lateral alone 
Parallel opposed lateral and lower anterior 
Phases of radiotherapy 
Total dose in Gy 
Fractionation schema 
I 
____________ ___;,_, ________ ....... 
Dose p~~r fraction 
Overall treatment time I 
I 
.. \ ,. 
Treatment_ breaks (In days and reason) I 
Intra-Radiotherapy Evaluation (Please use RTOG grading system and same w~g machine) 
Dates ~Veek-1 Week-2 Week.-3 Week-4- Week-S 
Oral 
mucositis 
grade 
(RTOG) 
Dvsnhama 
----·----1------·---·-
grade -·-····-· .. ··· .... -
.. 
-· 
(R'i'OG) 
Body 
Weight 
(inK~) 
Dry mouth 
. -··-· .... 
. ··-······. 
.. .. ... . 
--- _________ _:___ -----.. ·--·--·---- . 
Post-radiotherapy assessment on the last day 
Qol~ C-30 and QoL H· & N 35 questionnaife 
I 
I 
Week-6 Week-7 Week-8 
i 
: 
! 
I 
I 
i 
I 
I 
I 
I 
Week-
13/14 
~ 
EORTC OLO- H&N35 
Patients soto.etimes report that -they have the following symptoms or problems. Pl~ase indicate the· 
extent to which you have experienced tl;tese symptoms or problems during tb past week. Please 
answer by circling the number that best applies to you. I 
During tllne past week: Not A· 
I 
Quite Very 
at aD. little a bit much 
31. ~ve.:you had pain in yo~ mouth? · 1 2 3 4 
32. Have you h~d pak -~your jaw? ~ ·-· · 1 2 3 4 
(( 33. Have you had soreness in your mouth? 1 2 3 4 
34. Have you had a painful throat? 1 2 3 4' 
35. Ha:ve you had problems swallowing liquids? 1 2 3 4. 
36. I_Iave you had problems swall~~g pureed food? . 1 2 3 4 
37. Hav~: you had problems swallowing solid food? 1 2 3 4 
38. Hav~: you choked when swallowing? 1 2 .3 4 
39. Hav(~ you had problems With your teeth? 1 2 3 4 
40. HaVI~ you had problems opening your mouth wide? 1 2 3 4 
41. Hav·e you had a dry mouth? 1 2 3 4 
42. Have you had sticky saliva? 1 2 3 4 
i 
43. Have you had problems with·your sense-of smell? 1 
:J 
3 4 
44. Have you had problems with your sense of taste? 1 3 . 4 
45. Have you coughed? 1 2 3 4 
- ···-···-··--·-46.- --&1-e you been.hoarse? 1 2 
I 
3 4 
47. Have you felt ill? 1 2! 3 4 
21 48. Has your appearance bothered you? ·--· ·· .... ·· · · ··· · ·1 3 4 I 
I 
Please go on to the next page l 
! 
.• 
During the past week: Not A Quite Very 
.at all little a bit much 
49. Have you had trouble eating? 1 2 3 4 
50. Have you had trouble eating in front of your family? 1 2 3 4 
51. Have you had trouble eating in front of other people? 1 2 3 4 
52. Have you had trouble enjoying your meals? 2 3 4 
53. Have you had trouble talking to other people? 1 2 3 4 
54. Have you had trouble talkiD.g on the telephone? 1 2 3 4 
----------··----·-·-----· .. ··--- ·-··· -''. . a_- 55 . Have you had trouble having social contact with your family? 2 3 4 
....... 
56. Have you had trouble having social contact with friends? 2 3 4 
57. Have you had trouble going out in public? 1 2 3 4 
58. Have: you had trouble having physical 
contact with family or friends? 1 2 3 4 
59. Have you fe1t less interest in sex? 2 3 4 
60. H~v.~ yo'..l fcit less sexual enjoyment? 2 3 4 
During the past week: No Yes 
61. Have you used pain-killers? 1 2 
62. Have you taken any nutritional supplements (excluding vitamins)? 1 2 
-· .. --~--------·--- ..... -·-·--·-------- ....... 
63. Have you used a feecling tube? 1 2 
64. Have you lost weight? 1 2 
I 
65. Have you gained weight? I 2 
.I 
tO Copyright 1994 EORTC Quality of Lire Study Gt-oup, version 1.0 All rights reserved 
,.:::::;.--
ENGLISH 
EORTC QLQ-C30 (version 3) I 
We are interested in some things about you and your health. Please answer all of the I questions yourself by 
circling the n.umber that best applies to you. There are no "right" or "wrong11 answers. Tije information that you 
provide will remain strictly confidential. I 
I 
I 
Please fill in your initials: 
. Your birthdate (Day, Month, Year): 
Today's date (Day, Month, Year): 31 
Not at A Quite Very 
All Little a Bit Much 
1. Do you have any trouble doihg strenuous activities, 
like car~g.!_!l~~Y.Y.-~~9.J?P~~t~ag. or a suitcase? 2 3 4 
2. Do you have any trouble taking a long walk? 2 3 4 
... Do you have any trouble taking a short walk outside of the house? 2 3 4 .). 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
5. Do you. need help with eating, dressing, washing 
y()urself or using the toilet? 1 2 3 4 
During the past \Yeek: Not at A Quite Very 
All Little a Bit I'fiuch 
6. \V ere you limited in doing either your work 
or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other 
leisure time activities? 1 2 3 4 
8. Were-you-short-of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 2 3 4 
12. Have you felt weak? 2 3 4 
13. Have you lacked appetite? 2 3 4 
. .1 ~' _H~y~_y.QyJ~lt nauseated? .. 2 3 4 
15. Have you vomited? 2 3 4 
Please go on to the next page 
.. 
During the past week: 
16. Have you been constipated? 
17. Have you had diarrhea? 
18. Were you tired? 
19. Did pain interfere with your daily activities? 
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 
21. Did you feel tense? 
-·-----··-·--------·--··-·· ·-·----- -·--····--· . 
22. Did you worry? 
23. Did you f.~el initable? 
24. Did you feel depressed? 
25. Have you had difficulty remembering things? 
26. Has your physical condition or medical treatment 
interfered with your family life? 
27. Has your physical condition or medical treatment 
interfered with your social activities? . 
28. Has your physical condition or medical treatment 
caused you financial difficulties? 
Not at A 
All Little 
1 2 
2 
2 
2 
2 
2 
2 
1 ") ~ 
2 
1 2 
2 
1 2 
1 2 
i 
I_ 
I ENGLISH 
I 
Lte Very 
~Bit Much 
I 
I 3 4 
3 4 
3 4 
3 4 
3 4 
I 3 4 
I 
3 4 
I 
I 3 4 I 
! 
I 
I 
3 4 
I 3 4 I 
I 
: 
3 4 
3 4 
3 4 
For. _tb~ __ {Qllowi.J.lg _q~es.~ons pleas~ circle the number 
best appJi,es to you 
betwee1 
I 
I 
1 and 7 that 
29. How would you rate your overall health during the past week? 
2 3 4 5 6 7 
Very poor Excellent 
30. How would you rate your overall quality of life during the past week? 
2 3 4 5 6 7 
Very poor Excellent 
,~) Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
I 
I 
I 
I 
I 
. -'. 
TOXICfiY ASSESSMENT 
GRADEO GRADEl GRADE2 GRADE3 GRADE4 
SKIN No ~change over Follicular,faint,dull Tender,bright Confluent, m ist Ulceration 
.Baseline Erythema/Epilation/Dry Erythema.Patch. Desquamatio haemorrhage 
Desquamation Mod. Edema Necrosis 
Erthema!Mild Pain Mucositis Confluent Fi Ulceration 
Sero.Sang.Dis Mucositis Hemorrhage 
Req~Analgesic Req.Narcotic Necrosis. 
Mod.Dryness Complete. 
I 
Acute Salivary 
GLAND Thick Saliva!Metalic Taste Thick Saliva Dryness I Necrosis. 
LARYNX No Change Mild Hoarseness Pers.Hoarseness Whispered Speech ~arked Dyspnea 
Mild cough Refd.Otaigia.Cough. Throat pain. I Stridor. 
Erythema mucosa Anti tussive needed. Arytenoid.Edema Tracheostomy. 
I 
! 
i 
ESOPHAGUS No change Mild dysphagia Mod. Dysphagia Severe Dysphagia .cotplete Obstruction 
Or Odynophagia or Odynophagia or Odynophagia Ulc~ration, Fistula 
\VBC( X lOOO) > 4.5 3.0- < 4.5 2.0- < 3.0 l.O- 2.0 <1.0 
f'l'"EUTROPHHILS . 
( X-1000) ··· · · · > 1.9 
HE1\10GLOBIN > ll 
( GM o/o) 
PLATELET > 130 
(X 1000) 
1.5- < 1.9 
9.5- 11 
90- <130 
1.0- < 1.5 0.5- < 1.0 j <0.5 or Sepsis 
<9.5 Paccked cell Transfusir required 
I 
50-< 90 25- <50 <25 or S1ontaneous bleeding 
I 
.'f.-
GRADEO GRADE 1 GRADE2 
NAUSEANO.MITING None Nausea Transient Vomit 
DIAIUU-IEA None Transient Tolerable 
<2 days >2days 
ALOPECIA None Minimal P~tchy 
FEVER none <38 c 38-40 c 
_-.-.----------···--···-.:. ......... ·~ ·--··· ...... 
.. - . - ··- - . ----·-·- ·-·-··-········---- -········-·-- ...... ·•· ................ . 
GRADE3 
Requiring 
Treatrnen 
fntolerabl 
complete. 
>40C 
I 
i 
.I 
l 
I 
.I 
I 
·I 
I 
GRADE4 
[ntractable 
Vomiting 
Hemorrhagic 
Dehydration 
non reversible 
+ Hyp~tension 
·, 
Event 
none 
1 
increased stool 
frequency. occ:asiaoal 
blooHtreaked sto61S ot 
rectal cliSOOmfort 
(mcluomg hemauhoids) 
not requiring 
medi~ 
2 
increased stooi 
,1~c~qn~ •. Ple2ding. 
~ca'SclisCbarge. or 
rectal discOinfurt 
~amedic:rtion; ~~ 
ere Version 2..0 
"Pnli11i<!1t Daie! AprD 30, 1999 
pe:dim!tion, bleeding or 
lleCI"osis or o1ber life. 
fureatening 
®mplicd:imireqnirlng 
smg:U:al~ 
.·(e.~. ~~~y) 
Also cansider BeJ.lloo:hagefblee,ding:w.ifb gmde 3 or 4 thromoocyt~ ~en?Q';'·Y~$~~~g withont grade 3 or 4 tbrcmt.~~~ft9Jlellia, ~~ ~c ~ :mtfiaijmL 
NoU!S: Fi~ is ~ed sepanrtely as FIStnia..:tecta11anal - '' · 
Proctitis occon:ingmore than 90 days a:fter1he start of:mdilrtiOD. tll~y is ~din theRTOG/EORTC Late~"'"~ .... ~ .... Momidey Scarlng Scheme. (See 
AppenOix.IV) .. . . : . . 
Salivazy gland ~s none slightly1Liekened thick, TOpy, sticky 
· saliva; niay .have saliva; mmkedly a1tcred 
sligliilyaltered tJste 1aste; alt(:nrtion in diet 
. (e.g.,1Jletallic); -required' 
--t--~----···------·- --------··--··----~- _a~~~:fin.f:ds~ ~e. required · · · ·· · 
11one ~~~;~~- - ........ paitifulety&~ 
~-~mild . ~or ulcers, 1rot 
soreness in fhe absence can eat or sWallow 
oflesians 
acute salivary gland 
necrosis · 
~"Dl~ar. 
~_paf.~.<ll" 
entcl21mtiitional . 
snpport ~ PnJpllyJaetic 
imuhttion_ · 
p~tma:l~OJ::;, 'bleOOing 0'.!" 
l!tc:<rosis,CJ: otn.a-lif'e- · 
1hr~·· . 
c:ompli~anrecprlng 
snrgical :intervention 
(e.g.~_ colostOmy) 
-~.consiW:r Hemor.~elb1eeding wi'.h grade 3 or 4 tbromOOcytopeDia, BemOlrlla~e·g ~grade 3 ~4 tlJrj~>OC:vtPl~ia. H~on, Febrile 
none 1 ~sode in 24llouts 
over~ 
13 
2-5 Cjlisodes in 24 hm:trs 
over p:retreatment 
m.odetate severe 
mquirlngpamltetal 
mrtrlt.ion; or pb:ysiclogic 
~xequiling 
intensive cate; 
bemodynamic co'Dapse 
Revised March 23, 1998 
;_ 
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Appendix ill 
Performance Status Scales/Scores 
PERFOR:MANCE STATUS CRITERIA 
Kamofsky a~.:l Lans!Qr performa1Jce scores are intended to be multiples of 10. 
Score 
1 
3 
Restl:icted in physically 
sfrenuous activity but 
~bt.datofy and abie tD carry 
out vm of~ rtght or 
sederilary nab,lre,· e.g~ fight 
housev<'ork. offiCe \votk. 
Cal}ab!e of only fllllited 
self(:are, confined to bed or 
char more tmm 50% d 
wak1nghou~ 
Normal activity \Wth effort; 
seriie 'Signs or s~.mPtririts d 
disease. 
70 C;3:'esforsetf, unab1etocany · 7(} 
on no~adM!y c: dodve 
wcr"~· · 
.~ 
'"The conver.sion ct the Lansky to ECOG seal~ is intfiJnded fur NCI rep_pffitlg purpoSes on!y. 
Cancer Therapy Evaln:ltion Program 
Common Toxicity Criteria, V~on 2.0 
DCID, NCI, NIH, DHHS Marob 1998 
30 
CfC Version 2 .. 6 
PDll1liC!h Date: April30, 1999 
Revised MarclJ 23, 1998 
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-APPENDIX 8 
Patient Information and Consent Form 
Research Title : Phase Ill Randomized Control Trial Co paring Natural 
Honey in The Management of Radiation ucositis 
Among Patients Undergoing Radical Ra iotherapy for 
Nasopharyngeal Cancer. 
Researcher's Name : Dr. Biswa Mohan Biswal 
Introduction 
You are invited to take part voluntarily in a research study of ure natural honey 
in the management of .. radiation mucositis. Honey is a mixtu of flower nectar 
and tile body part mfioney·· ·bee.· ·Honey is an old remedy in many disease 
including hurn and oral disease. Recent studies shows that ure natural honey 
can prevent the development of severe year radiation mucosi is. Honey being a 
nutritional supplement rich in calorie, help cancer patient to g in energy. We are 
going to use honey to a gro"up of patients undergoing radioth apy that aimed to 
prevent mucositis. Before agreeing to participate in this re earch study, it is 
important that you. read and understand this form. It desc,ibes ·the purpose, 
procedures, benefits, risks, discomforts, and precautions of he study. It also 
describes the alternative procedures that are available to yo and your right to 
\Vi~hdra\v from the study at anytime. If you participate, you \lifil receive a copy of 
thts fonn to keep for your reco;d. 
Your parcipation in this study is expected to last up to 6- 8 'eeks. Up to 120 
patients will be participating in this study. 
V\/hat: is nasopharyngeal cancer? 
-·Na-soph-aryn-geal-6-anceris·-one··of the most common cancer a ong Malaysian 
men arising from the nasopharynx. The nasopharynx is prese t behind the nose 
and at the top of the throat. This cancer is very common amon Chinese and 
Malay race. Once started, it can spread to neck nodes and tha to other parts of 
the body if not treated by radiotherapy. 
Wha~t is mucositis? 
Mucositis is the common symptom develop among patients th se undergoing 
radiotherapy to the head and neck area. There may be sympt ms of sore throat, 
painful swallowing and ulceration of the inner !inning of the m uth and throat. 
I 
PurposE~ of the Study 
The purpose of this study are to determine if pure natural honey an prevent the 
developrnent of symptomatic radiation mucositis. 
Qualification to Participate 
The doctor in charge of this study or a member of the study sta has discussed 
with you the requirements for participation in this study. It ·is im ortant that you 
are completely truthful with the doctor and staff about you heal h history. You 
shou1d not participate if-1 this study if you do not meet all qualifica ons. 
----·-----·--·----·-t Some of the requirements to enter in this study are-
1:1 Nasopharyngeal cancers. 
tt HPE evidence of cancer. 
tt \/\filing to sign consent form to participate. 
t& VVilling for full course of radical radiotherapy. 
Yoi..! cannot participate in this study if 
..: 
I 
I 
I 
! 
I 
I 
·,., 
t...t You receive previous radiotherapy. · I 
~~ You are suffering frorn Co-morbid connective vascular diseh
1 
.... ses, diabetes. 
tl Insane person. ,
I 
i 
i 
Study Procedures i 
AtyouLfiL$.LYi§_tt__,jf..y.9JL99f~-~- .t.Q.. palijc!p~te in. this st~dy the d<;> or incharge will 
perform routine clinical examination, review your x-rays, biopsy eport and other 
relevant. investigation necessary for you.lf you are selec ed for radical 
radiotherapy, you wilt be asked to answer our questions to asse your 
wellbeing. Radiotherapy treatment _consist of five treatments p3week to a total 
of 7 - 8 week. The patient in this study group will be given 20 I of pure natural 
honey, ·15 minutes before radiotherapy, 15 minutes after radioth rapy and 6 hour 
after radiotherapy. During the period of radiotherapy your d ctor I research 
assistant will check your oral cavity for the development of mu sitis everyweek. 
We record your body weight everyweek during the course of ra iotherapy. 
EollowjngJ:heJ:reatment,_the .. study __ doctor or. his representatives ay contact you 
to obtain information about your experiences during the trial or t e status of your 
health and quality of life. 
Risks 
Honey is the natural product being used for food supplement don't have any 
significant additional side-effect unless you are allergic to honey Radiotherapy to 
the head & neck area carries similar risks to both study and cont~ I arm. 
Reporting Health Experiences. 
If you have any injury, bad effect, or any other unusual health ~1 perience during 
this study, make sure that you immediately tell the nurse or uf. Biswa Mohan 
Biswal at 09-7663208@ HP. 019-9669165. You can c~ll at anyti e, day or night, 
to report such health experiences. 
~~---other-=rreatments--··----- ··- ·· . 
If you do not want to take part in this study, your illness or 'ondition will be 
treated vvith radical radiotherapy alone. The study doctor ca dis~uss these 
treatments and therapies with you. . 
Participation in the Study I 
I 
i 
. I 
Your taking part in this study is entirely.voluntary. You may refu~ to tal<e part in 
the study or you may stop participation in the study at anyti e, Vlfithout any 
panc:lty or loss of benefits to which you are othervvise entitled. 1 
Your participation also may be stopped by the study doctor or sponsor without 
yourconsent . i 
If you stop being part of this Study, the study doctor or one of lhe staff member 
wm talk to you about medical issues regarding the stopping of ytur participation. 
I 
I 
Possible Benefits 
I 
I 
Study agent will be provided to you at no cost to you. ou may receive 
information about your health, physical examination finding an laboratory tests 
to be done in this study. 
Although honey being used for the radiation mucositis, there is o guarantee that 
you will receive any medical benefit. 
.. 
I 
Questions 
If you have any question about this study or your rights, please c ntact ; 
1. Dr. Biswa Mohan Biswai.MD, Consultant Clinical Oncolog st 
Department of Nuclear, Medicine, Radiotherapy & Oncolo y 
Hospital Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, 
Malaysia. 
09-7663208 (Office), HP: 019-9669165, 
(E~mail biswa@kb.usm.my) 
2. Dr. Gurcharan Singh K.her~ Consultant Clinical Oncologist D ara Specialist 
Hospital.119. J al~ ss 20/10 Damansara Utama, 4 7 400 Petaling J ya, Selangor, 
--------------·-Mataysia. -----···· -····· · 
03-77223880 (Office), HP: 012-3865140 if (e-mail: guru1@tm;net.my) 
.., 
.). Dr. C.R B~a Devi, Consultant Clinical Oncologist 
Department of Radiotherapy & Oncology 
Hospital Umum, Kuc~g, Sarawak. 
(e-mail: devina@pc.jarin&,.mv) 
4. Prof. Madya Yoke Ching Foo.Associate Professor (UPM) & Clr· cal Oncologist. 
Department of Radiotherapy & Oncology, General Hospital K a Lumpur 
Jalan Pahang, I<.uala Lumpur. 
(·e-lnail: y.c foo@ hotmail.com) 
Confidc~ntialty 
Your~~~di~a; i~nf~~~~ii~~ ~ill be kept confidential by the studyl doctor and staff 
and will not be made publicly available unless disclosure is required by law. 
Data obtained from this study that does not identify you individ ally will be given 
to the investigation and/or its representatives and may be publis ed 
Your original medical records may be reviewed by the sp nsor and/or its 
represemtatives, the Ethical Review Board for the this stud , and regulatory 
authorities. 
By -signing-this-consent--form~ ····you authorize the record 
storagE~ and data transfer described aboved. 
information 
Signatures 
To be entered into the study, you or a legal representative m st sign and date 
the signature page (see Appendix 1) 
-------------·-------·--------···--·- . ··-· . . ... 
.. 
; 
Appendix 1 
Patient Consent Form (Signature Page) 
Research Title : Phase Ill randomized control trial comparin natural honey 
in the management of radiation mucositis mong patients 
undergoing radical radiotherapy for nasop aryngeal 
Cancer. 
Researcher'S Name : Dr. Biswa Mohan Biswal 
To become a part this study, you or your legal representative m t sign this 
page. 
By signing this page, 1 .. am confirming the following: 
~---'lt~·-t-have-re-act-ait-ofihe··information in this Patient lnformatio and Consent 
Form including any information regarding the risk in this Ludy and I have 
had time to think about it. 
~-~ All of my questions have been answered to my satisfactio . \. 
tt I voluntarily agree to be part of this research study, to foil w the study 
procedures, and to prqvide necessary information to the d ctor, nurses, or 
other staff members, as requested. 
!l I may freely choose to stop being a part of this study at a ime. 
~X I have received a copy of this Patient Information and Co. sent Form to 
keep for myself. 
Patsent LC Number (new) 
Signature of patient or Legal Representative 
Name (~ Signature of Individual Conductiong 
Informed Consent Discussion (Print or Type) 
Name & Signature of witness 
Notes: 
Pz.tk~nt h1 ~ia;s and 
Patfent hi mber 
Patient i.d No. (old} 
Date (dd Myy) (add 
ime of da if appropriate) 
Myy) 
Date ( dd Myy) 
